How much revenue does Jiangsu Hengrui Medicine make?

Jiangsu Hengrui Medicine reported 31.63 billion CNY in revenue for fiscal year 2025, up 13.0% from 27.98 billion CNY in fiscal year 2024. In Q1 2026 revenue was 8.14 billion CNY.

Where does Jiangsu Hengrui Medicine make most of its revenue?

China: 85% of revenue by region in fiscal year 2025, followed by Foreign (15%).

What companies are similar to Jiangsu Hengrui Medicine?

Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Sichuan Biokin Pharmaceutical Co.,Ltd. (688506.SS), Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SS), Junshi BIO (688180.SS), Dizal (Jiangsu) Pharmaceutical Co., Ltd. (688192.SS).

Jiangsu Hengrui Medicine Co., Ltd. (600276.SS) Stock

About Jiangsu Hengrui Medicine Co., Ltd.

Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. The company develops medicines in the areas of oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmol...

At a glance

Jiangsu Hengrui Medicine reported revenue of 31.63 billion CNY for fiscal year 2025, up 13.0% from fiscal year 2024, and net income of 7.71 billion CNY. In Q1 2026 (the quarter ended March 31, 2026) revenue was 8.14 billion CNY, up 13.0% from a year before. China was its largest region in fiscal year 2025, with 85% of revenue.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.